Cargando…

Systemic Administration of Erythropoietin Inhibits Retinopathy in RCS Rats

OBJECTIVE: Royal College of Surgeons (RCS) rats develop vasculopathy as photoreceptors degenerate. The aim of this study was to examine the effect of erythropoietin (EPO) on retinopathy in RCS rats. METHODS: Fluorescein angiography was used to monitor retinal vascular changes over time. Changes in r...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Weiyong, Chung, Sook H., Irhimeh, Mohammad R., Li, Shiying, Lee, So-Ra, Gillies, Mark C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132022/
https://www.ncbi.nlm.nih.gov/pubmed/25119659
http://dx.doi.org/10.1371/journal.pone.0104759
_version_ 1782330553433849856
author Shen, Weiyong
Chung, Sook H.
Irhimeh, Mohammad R.
Li, Shiying
Lee, So-Ra
Gillies, Mark C.
author_facet Shen, Weiyong
Chung, Sook H.
Irhimeh, Mohammad R.
Li, Shiying
Lee, So-Ra
Gillies, Mark C.
author_sort Shen, Weiyong
collection PubMed
description OBJECTIVE: Royal College of Surgeons (RCS) rats develop vasculopathy as photoreceptors degenerate. The aim of this study was to examine the effect of erythropoietin (EPO) on retinopathy in RCS rats. METHODS: Fluorescein angiography was used to monitor retinal vascular changes over time. Changes in retinal glia and vasculature were studied by immunostaining. To study the effects of EPO on retinal pathology, EPO (5000 IU/kg) was injected intraperitoneally in 14 week old normal and RCS rats twice a week for 4 weeks. Changes in the retinal vasculature, glia and microglia, photoreceptor apoptosis, differential expression of p75 neurotrophin receptor (p75(NTR)), pro-neurotrophin 3 (pro-NT3), tumour necrosis factor-α (TNFα), pigment epithelium derived factor (PEDF) and vascular endothelial growth factor-A (VEGF-A), the production of CD34(+) cells and mobilization of CD34(+)/VEGF-R2(+) cells as well as recruitment of CD34(+) cells into the retina were examined after EPO treatment. RESULTS: RCS rats developed progressive capillary dropout and subretinal neovascularization which were accompanied by retinal gliosis. Systemic administration of EPO stabilized the retinal vasculature and inhibited the development of focal vascular lesions. Further studies showed that EPO modulated retinal gliosis, attenuated photoreceptor apoptosis and p75(NTR) and pro-NT3 upregulation, promoted the infiltration of ramified microglia and stimulated VEGF-A expression but had little effect on TNFα and PEDF expression. EPO stimulated the production of red and white blood cells and CD34(+) cells along with effective mobilization of CD34(+)/VEGF-R2(+) cells. Immunofluorescence study demonstrated that EPO enhanced the recruitment of CD34(+) cells into the retina. CONCLUSIONS: Our results suggest that EPO has therapeutic potentials in treatment of neuronal and vascular pathology in retinal disease. The protective effects of EPO on photoreceptors and the retinal vasculature may involve multiple mechanisms including regulation of retinal glia and microglia, inhibition of p75(NTR)-pro-NT3 signaling together with stimulation of production and mobilization of bone marrow derived cells.
format Online
Article
Text
id pubmed-4132022
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-41320222014-08-19 Systemic Administration of Erythropoietin Inhibits Retinopathy in RCS Rats Shen, Weiyong Chung, Sook H. Irhimeh, Mohammad R. Li, Shiying Lee, So-Ra Gillies, Mark C. PLoS One Research Article OBJECTIVE: Royal College of Surgeons (RCS) rats develop vasculopathy as photoreceptors degenerate. The aim of this study was to examine the effect of erythropoietin (EPO) on retinopathy in RCS rats. METHODS: Fluorescein angiography was used to monitor retinal vascular changes over time. Changes in retinal glia and vasculature were studied by immunostaining. To study the effects of EPO on retinal pathology, EPO (5000 IU/kg) was injected intraperitoneally in 14 week old normal and RCS rats twice a week for 4 weeks. Changes in the retinal vasculature, glia and microglia, photoreceptor apoptosis, differential expression of p75 neurotrophin receptor (p75(NTR)), pro-neurotrophin 3 (pro-NT3), tumour necrosis factor-α (TNFα), pigment epithelium derived factor (PEDF) and vascular endothelial growth factor-A (VEGF-A), the production of CD34(+) cells and mobilization of CD34(+)/VEGF-R2(+) cells as well as recruitment of CD34(+) cells into the retina were examined after EPO treatment. RESULTS: RCS rats developed progressive capillary dropout and subretinal neovascularization which were accompanied by retinal gliosis. Systemic administration of EPO stabilized the retinal vasculature and inhibited the development of focal vascular lesions. Further studies showed that EPO modulated retinal gliosis, attenuated photoreceptor apoptosis and p75(NTR) and pro-NT3 upregulation, promoted the infiltration of ramified microglia and stimulated VEGF-A expression but had little effect on TNFα and PEDF expression. EPO stimulated the production of red and white blood cells and CD34(+) cells along with effective mobilization of CD34(+)/VEGF-R2(+) cells. Immunofluorescence study demonstrated that EPO enhanced the recruitment of CD34(+) cells into the retina. CONCLUSIONS: Our results suggest that EPO has therapeutic potentials in treatment of neuronal and vascular pathology in retinal disease. The protective effects of EPO on photoreceptors and the retinal vasculature may involve multiple mechanisms including regulation of retinal glia and microglia, inhibition of p75(NTR)-pro-NT3 signaling together with stimulation of production and mobilization of bone marrow derived cells. Public Library of Science 2014-08-13 /pmc/articles/PMC4132022/ /pubmed/25119659 http://dx.doi.org/10.1371/journal.pone.0104759 Text en © 2014 Shen et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Shen, Weiyong
Chung, Sook H.
Irhimeh, Mohammad R.
Li, Shiying
Lee, So-Ra
Gillies, Mark C.
Systemic Administration of Erythropoietin Inhibits Retinopathy in RCS Rats
title Systemic Administration of Erythropoietin Inhibits Retinopathy in RCS Rats
title_full Systemic Administration of Erythropoietin Inhibits Retinopathy in RCS Rats
title_fullStr Systemic Administration of Erythropoietin Inhibits Retinopathy in RCS Rats
title_full_unstemmed Systemic Administration of Erythropoietin Inhibits Retinopathy in RCS Rats
title_short Systemic Administration of Erythropoietin Inhibits Retinopathy in RCS Rats
title_sort systemic administration of erythropoietin inhibits retinopathy in rcs rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4132022/
https://www.ncbi.nlm.nih.gov/pubmed/25119659
http://dx.doi.org/10.1371/journal.pone.0104759
work_keys_str_mv AT shenweiyong systemicadministrationoferythropoietininhibitsretinopathyinrcsrats
AT chungsookh systemicadministrationoferythropoietininhibitsretinopathyinrcsrats
AT irhimehmohammadr systemicadministrationoferythropoietininhibitsretinopathyinrcsrats
AT lishiying systemicadministrationoferythropoietininhibitsretinopathyinrcsrats
AT leesora systemicadministrationoferythropoietininhibitsretinopathyinrcsrats
AT gilliesmarkc systemicadministrationoferythropoietininhibitsretinopathyinrcsrats